Description
Rosuvastatin is a competitive inhibitor of the enzyme HMG-CoA reductase, having a mechanism of action similar to that of other statins
Rosuvastatin is indicated as adjunctive therapy to diet to reduce elevated Total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate.
Rosuvastatin is a Hydrophilic Statin
PROPOSED INDICATIONS
- Primary hypercholesterolemia and mixed dyslipidemia
- Hypertriglyceridemia
- Homozygous familial hypercholesterolemia
- This should be administered strictly with the prescription and advise of medical practitioners only.
